Most Mechanisms of B-Cell Damage (Hyperglycemia) Overlap with Causes of Vascular Disease : Provides Logic for Treatment Regimes and CV Benefits.

Slides:



Advertisements
Similar presentations
Remissione del diabete tipo 2: Terapia Medica Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.
Advertisements

Blood glucose levels and Vascular Disease. Chronic elevation of blood glucose levels leads to the endothelium cells taking in more glucose than normal.
INSULIN STRATEGIES IN TYPE 2 DIABETES. The epidemic of type 2 diabetes and the recognition that achieving specific glycemic goals can substantially reduce.
What is Diabetes?.
LONG TERM BENEFITS OF ORAL AGENTS
Therapy of Type 2 Diabetes Mellitus: UPDATE
Diabetes Mellitus (Lecture 2). Type 2 DM 90% of diabetics (in USA) Develops gradually may be without obvious symptoms may be detected by routine screening.
Public Health Issues in Canada. What do you think are the current issues? 1.Consider if the issue is affecting more than a few individuals 2.Is it something.
The entwined factors Syndrome X. hypertension diabetes heart disease “trunkal” obesity cancers of all types Gene that lends predisposition to Syndrome.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Current Therapy for Type II Diabetes. New ADA Guidelines- 4/20/12 Inzucchi, Diabetologia 4/20/12 SU most prominent- First, reading L to R Added back.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 5.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Diabetes Mellitus 101 for Medical Professionals
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 4 Stan Schwartz MD, FACP, FACE.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
What’s a Concept map?. Concept Map: Objective: To help you see the link between the terms and ideas about which you are learning AND to review what you.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Lifestyle Modifications
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.
Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.
Type I Diabetes Juvenile diabetes – develops early in life Beta cells in pancreas do not produce insulin Genetic predisposition – virus may trigger an.
Current Classification of DM Update on Diabetes Classification Celeste C. Thomas, MD, MSa,*, Louis H. Philipson, MD, PhD,Med Clin N Am 99 (2015) 1–16.
Β-Cell (Islet Cell) Classification Model- Implications for Therapy: Targets for Therapies/ New Guidelines Medication Choice Based on 1.Glycemic Efficacy.
A Process Of Precision Medicine- Matching Right Drug to Right Patient.
Utilizing Anti-diabetic Agents to Manage Cardiovascular Disease in T2DM Patients James LaSalle, D.O., FAAFP.
CV Risk of SU and Insulin
Avoid Early Insulin Therapy (except in Ketosis-prone) Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Blood glucose rises.
The β-Cell Centric Classification of DM
Post-bariatric Surgery Hypoglycemia : A Descriptive Analysis
Once Upon a Time, Insulin Resistance was Adaptive… but Not Today
A Process Of Precision Medicine- Matching Right Drug to Right Patient
NATURAL HISTORY OF BETA CELL FAILURE IN T2DM
Beta-Cell Classification of Diabetes and the Egregious Eleven: Logic for Newer Algorithms/ Processes of Care The Role of Newer Anti-Diabetes Medications.
Initiation of Basal Insulin- not bolus
In T2DM, β-Cell Mass in Islets is Significantly Reduced
Blood Glucose Noadswood Science, 2016.
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Diabetes Mellitus Nursing Management.
A Clinical-Translator’s Point-of-View:
Unified Theory of Diabetes and All Its Complications
Targets for Therapies/ New Guidelines
Treatment of Type 2 Diabetes: Pathophysiology Conclude: do so without Hypoglycemia or Visceral Fat Weight Gain 1.
Pushback What about ‘pure’ Insulin Resistance Syndromes?
Diabetes Mellitus.
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
CV Risk of SU and Insulin
Blood glucose levels and obesity
Diabetes and Stroke.
Macrovascular Complications Microvascular Complications
Value of construct 1. Fits with Harry Keen’s construct
Choice of Therapy MYTH: “Most Patients with ‘T2DM’ will eventually
↑- likely due to hypoglycemia and weight gain
Beta-Cell Classification of Diabetes and the Egregious Eleven: Logic for Newer Algorithms/ Processes of Care The Role of Newer Anti-Diabetes Medications.
Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Undue Or bolus Hypoglycemia Symptomatic or not!
CV Outcome Studies Empa-reg Leader Pio Stroke (Proactive) Bromocriptine Metformin-UKPDS.
What do I remember? What is the effect of chronically elevated blood glucose levels on blood vessels? What cardiovascular diseases are a consequence of.
Strategies for the Practical Management of Type 2 Diabetes
Once Upon a Time, Insulin Resistance was Adaptive… but Not Today
Type 2 Diabetes Subgroup
Not just cost of a dose, but cost benefit of CV/Complication reduction
Presentation transcript:

Most Mechanisms of B-Cell Damage (Hyperglycemia) Overlap with Causes of Vascular Disease : Provides Logic for Treatment Regimes and CV Benefits of DM Meds

Therapeutic Principles Across Continuum of Care eg: Right Drug for Right Patient and vice versa DETERMINE INSULIN DEPENDENCY-(DKA, c-peptide,?other DETERMINE Patient Specific Mechanisms of Hyperglycemia Treat ? For prevention/ pre-diabetes Treat as many of the Egregious 11 Targets as needed, least # of agents, lowest sugars/HgA1c as possible without undue weight gain or hypoglycemia Early Combination Therapy- Patient Centric- even 6.5-7.5 HgA1c Efficacy, - CV event reduction, Weight Loss (Not first-second-third line; Not competition between classes) Can Modify therapy after 1m-not 3m-use Fructosamie Stabilize, preserve β-cells, the CORE DEFECT ( NO SU/GLINIDES)- Ideally agents will have potential to synergistically decrease in CV risk factors / outcomes

2. No need for Early Insulin 3. If need Insulin, Continue Therapeutic Principles Across Continuum of Care eg: Right Drug for Right Patient and vice versa Delay Need for Insulin 2. No need for Early Insulin 3. If need Insulin, Continue Non-Insulin RX (Avoids need for Meal-Time Insulin- (Decrease Risk Hypoglycemia 85%- Garber) 4. Get Patients off insulin who had been given early Insulin

Choice of Therapy Allows us to Correct a myth MYTH: “Most Patients with ‘T2DM’ will eventually progress to insulin because of inexorable β-Cell loss” - But data obtained on SU=apoptosis; Hyperinsulinism with weight gain - Think of bariatric patients – no insulin after 25 years DM/ 20 years insulin - Most patients dying with DM have > 20% β-Cell mass- Butler - Need to remove >80% pancreas to leave patient with DM post-op

But 15-20 years ago told to use EARLY insulin, rather than delay and use Insulin Late Decrease Glucotoxicity AndWe’ve been taught: ‘Beta cell failure occurs much earlier in the natural history of type 2 diabetes and is more severe than previously appreciated’ Helps ‘confirm’ impression that most T2DM patients will need insulin

Avoid Early Insulin Therapy (except in Ketosis-prone) Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Blood glucose rises Undue Basal Or bolus Insulin =Overinsulinized Patient eats too much Or simple sugars Hypoglycemia Symptomatic or not! INCREASED APPETITE

Exquisitely controlled levels of insulin released into the portal vein NOTE: There is NO perfect Exogenous Insulin: All result in HyperInsulinemia and Potential Hypoglycemia Exquisitely controlled levels of insulin released into the portal vein Fine-tuned, physiologically appropriate insulinemia Endogenous Insulin ‘Obligatory’ excess peripheral insulin to get modicum of reduced hepatic glucose production Exogenous Insulin Insulin Resistance β-cell Dysfunction ------- Potential β-cell Exhaustion Hypoglycemia Obesity Hyperinsulin-emia Atherosclerosis All because all insulin results in hyperinsulinemia with risk of negative consequences Weight gain Hypertension Dyslipidemia Cancer Chronic Inflammation Type II Diabetes